Lv6
1760 积分 2020-12-07 加入
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
7天前
已关闭
Management of Intermediate-Stage Hepatocellular Carcinoma
8天前
已完结
Intermediate hepatocellular carcinoma: new horizons and prospects for our patients
8天前
已完结
Management of portal hypertension in patients receiving atezolizumab-bevacizumab for hepatocellular carcinoma
23天前
已关闭
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets
1个月前
已完结
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials
1个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
1个月前
已完结
Changing treatment patterns for hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results–Medicare study
2个月前
已完结
The combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer
2个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
